TRIMTECH Therapeutics
Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.
- Join TRIMTECH Scientist, Jonathan Benn, at the next Cambridge New Therapeutics Forum and learn more about our aggregate-selective targeted protein degrader programme, offering a small molecule approach to combat neurodegenerative diseases. Register here: www.eventbrite.co.uk/e/advances-i...
- JPM Healthcare Conference Week 2026 is well underway in San Francisco! Our CEO Nicki Thompson presented at the Cambridge x London Life Sciences Showcase, part of RESI JPM Healthcare Week 2026.
- Happy New Year! We’re kicking off 2026 in San Francisco at Sachs’ 9th Annual Neuroscience Innovation Forum and JPM Healthcare Conference Week. Schedule a meeting 📩 trimtechtherapeutics.com/contact/
- From all of us at TRIMTECH, happy holidays! 🎄 We’re incredibly proud of what our team has achieved and look forward to another exciting year ahead!
- Delighted to welcome Alison Lawton as Chair of our Board. With 35+ years in global biotech and pharma, she brings deep development, operational and leadership experience to support TRIMTECH’s next stage of growth: shorturl.at/xXXbC
- Our academic co-founders have published in Nature Communications - detailing the science behind TRIMTECH’s TRIMTAC® degraders. Congrats to Will, Leo, Dean, Jonathan, and all collaborators advancing state-selective protein degradation: www.nature.com/articles/s41...
- We’re absolutely delighted to have been awarded ‘Seed Raise of the Year’ at last night’s LSX European Lifestars Awards!
- Our team will be in London during Jefferies Global Healthcare Conference Week, kicking off discussions across the global healthcare sector as part of London Life Sciences Week!
- We’re delighted to welcome Dr. Mike Hutton to our SAB! Mike joins Prof. Alessio Ciulli FRS and Dr. Adam Gilbert in advancing our mission to develop novel therapeutics that target protein aggregates in neurodegenerative diseases. Read more: trimtechtherapeutics.com/trimtech-the...
- Meet our Senior Director of Chemistry, Dr Andrea Testa, and discover his journey in targeted protein degradation research in this blog: trimtechtherapeutics.com/meet-the-tea...
- We’ll be in Barcelona for the 2nd Annual Drug Discovery Chemistry Europe. Catch our Head of Exploratory Biology, Dr Dean Clift, on Day 1 in the Next-Gen Degraders & Molecular Glues track ➡️https://www.drugdiscoverychemistry.com/europe/degraders-molecular-glues
- CEO Dr Nicki Thompson is in Boston for the 8th Annual TPD and Induced Proximity Summit. Catch her sessions today to learn more about TRIMTECH’s work in TPD.
- We’ve been awarded ‘Start-up of the Year’ at the annual TPD & Induced Proximity Awards 🏆 Learn more about our pipeline of small-molecule, aggregate-selective, targeted protein degraders for the treatment of neurodegenerative diseases: trimtechtherapeutics.com/science/
- Only a few weeks to go until the 8th Annual TPD and Induced Proximity Summit! Learn more about our pipeline of small-molecule, aggregate-selective, targeted protein degraders for the treatment of neurodegenerative diseases: trimtechtherapeutics.com/science/
- Dr Damian Crowther, Head of Research, will be at Alzheimer’s Research UK’s Drug Discovery Alliance Networking Event, giving the plenary session on ‘Drug Discovery and the Future of Drug Development’. Learn more: www.alzheimersresearchuk.org/about-us/how...
- Our CEO, Nicki Thompson, participated in a panel discussion on ‘Innovations in Protein Degradation in the Biotech Sector’ at Discovery on Target in Boston, highlighting how novel degrader modalities are driving innovation and enabling pursuit of challenging targets. #BostonDOT #TPD
- We’re incredibly proud to be one of Fierce Biotech’s #Fierce15 – testament to our approach and the milestones our team has already achieved! Our goal is to develop cost-effective, disease-modifying treatments for common, aggregation-driven diseases. More: shorturl.at/IRTJO
- 21 Sep is #WorldAlzheimersDay, part of #WorldAlzheimersMonth. Over 55M people live with dementias, yet the need for cost-effective, disease-modifying treatments remains critical. TRIMTECH is advancing small molecule, aggregate-selective, targeted protein degraders 👉 trimtechtherapeutics.com
- Next week our CEO Nicki Thompson will be in Boston for Discovery on Target. Arrange a meeting: trimtechtherapeutics.com/contact/ #BostonDOT
- A busy couple of weeks ahead for the TRIMTECH team – scroll through to see where we’ll be this September ➡️
- EFMC-ASMC 2025 is well underway in Portugal! Join Senior Director of Chemistry, Dr Andrea Testa, at the 12th EFMC Young Medicinal Chemists’ Symposium, organised with the Young Scientist Network. Get in touch ➡️ trimtechtherapeutics.com/contact/
- We’ve been selected as a finalist for ‘Seed Raise of the Year’ at the LSX European Lifestars Awards. Earlier this year we closed a $31M (£25M) seed round, to support development of our protein degrader pipeline ➡️ informaconnect.com/european-lif...
- Excited to introduce our SAB! Professor Alessio Ciulli (SAB Chair) and Dr Adam Gilbert. Both are global leaders in targeted protein degradation, providing strategic guidance to advance our TRIMTAC and TRIMGLUE degraders and small molecule therapeutic pipeline. More: shorturl.at/f76pR
- Starting this Sunday, Dr Andrea Testa, Senior Director of Chemistry, will be in Portugal for EFMC-ASMC 2025 and the 12th EFMC Young Medicinal Chemists’ Symposium. Arrange a meeting with Andrea ➡️ trimtechtherapeutics.com/contact/
- If you haven’t already, check out this interview in Drug Discovery World – the first in a new series spotlighting updates from the Cambridge life sciences community. CEO Nicki Thompson discussed TRIMTECH’s small molecule approach and its transformative potential. More: shorturl.at/Gh009
- We’ve been featured in Business Weekly’s latest #Killer50 #Ones2Watch list, which highlights high-potential, fast-growing disruptive companies in the region’s life sciences sector. Learn more about our work and progress here: trimtechtherapeutics.com/science/
- Proud to be shortlisted for ‘Startup of the Year’ in this year's Business Weekly Awards! Following our $31M seed financing, we are developing our pipeline of aggregate selective degraders to treat neurodegenerative and inflammatory diseases.
- We’re delighted to feature in the first of Drug Discovery World’s new series spotlighting Cambridge life sciences. Our CEO Nicki Thompson discussed the growing excitement around TRIMTECH and what makes our approach so unique. Read more: shorturl.at/Gh009
- Leo James elected Fellow of the Royal Society We are delighted to congratulate our co-founder, Leo James, on his election as a Fellow of the Royal Society, one of the highest honours for a UK scientist, recognising exceptional contributions to science. tinyurl.com/2y4t3kx8
